Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Regulatory Affairs
Return to: PBR Home | Regulatory Affairs

Sobi secures European Commission approval for new dosing frequency of Orfadin

Published 03 February 2017

The European Commission (EC) has approved a reduced dosing frequency for Swedish Orphan Biovitrum International's (Sobi) Orfadin (nitisinone) from twice daily to once daily, in people with hereditary tyrosinemia type 1 (HT-1) with a body weight >20 kg.

Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head of Research & Development at Sobi, said: “Sobi has a long-term commitment to improve the lives for people affected by hereditary tyrosinemia type 1, and the above modified dosing regimen is a further step in this journey."

The approval is based on the results of a clinical study in 18 people with HT-1, comparing a four week once-daily and four week twice daily dosing regimen.

The study showed comparable blood-levels of nitisinone, as well as safety and efficacy for these two regimens. There was insufficient data (few people below 20 kg bodyweight were enrolled in the study) to be able to compare the two regimens in people below 20 kg. 

About Orfadin

People with hereditary tyrosinemia type 1 (HT-1) have problems breaking down an amino acid called tyrosine. Toxic by-products are formed and accumulate in the body, which can cause liver, renal and neurological complications. Approximately 1,000 persons worldwide are identified as living with HT-1 today.

Orfadin® (nitisinone) blocks the breakdown of tyrosine, thereby reducing the amount of toxic tyrosine by-products in the body. Patients must maintain a special diet in combination with Orfadin treatment as tyrosine is not adequately broken down. Orfadin is a proprietary product and is developed by and made available globally by Sobi.

Before Orfadin became available, the survival rate in HT-1 was 29 per cent after two years for children who developed symptoms before two months of age. After the introduction of Orfadin, the survival rate is 93 per cent after two years in patients with treatment initiation before two months of age.



Source: Company Press Release